Chanisa Kiatsurayanon

Chanisa Kiatsurayanon


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Hai Le Thanh NGUYENHai Le Thanh NGUYEN
Hai Le Thanh NGUYEN
Juan Valentin Trujillo PaezJuan Valentin Trujillo Paez
Juan Valentin Trujillo Paez
YUYoshie Umehara
Yoshie Umehara
HYHainan Yue
Hainan Yue
GPGe Peng
Ge Peng
François NiyonsabaFrançois Niyonsaba
François Niyonsaba
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that exhibits a complex interplay of skin barrier disruption and immune dysregulation. Patients with AD are susceptible to cutaneous infections that may progress to complications, including staphylococcal septicemia. Although most studies have focused on filaggrin mutations, the physical barrier and antimicrobial barrier also play critical roles in the pathogenesis of AD. Within the physical barrier, the stratum corneum and tight junctions play the most important roles. The tight junction barrier is involved in the pathogenesis of AD, as structural and functional defects in tight junctions not only disrupt the physical barrier but also contribute to immunological impairments. Furthermore, antimicrobial peptides, such as LL-37, human β-defensins, and S100A7, improve tight junction barrier function. Recent studies elucidating the pathogenesis of AD have led to the development of barrier repair therapy for skin barrier defects in patients with this disease. This review analyzes the association between skin barrier disruption in patients with AD and antimicrobial peptides to determine the effect of these peptides on skin barrier repair and to consider employing antimicrobial peptides in barrier repair strategies as an additional approach for AD management.

25 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
YUYoshie Umehara
Yoshie Umehara
CKChanisa Kiatsurayanon
Chanisa Kiatsurayanon
Juan Valentin Trujillo PaezJuan Valentin Trujillo Paez
Juan Valentin Trujillo Paez
PCPanjit Chieosilapatham
Panjit Chieosilapatham
GPGe Peng
Ge Peng
François NiyonsabaFrançois Niyonsaba
François Niyonsaba
Itch or pruritus is the hallmark of atopic dermatitis and is defined as an unpleasant sensation that evokes the desire to scratch. It is also believed that itch is a signal of danger from various environmental factors or physiological abnormalities. Because histamine is a well-known substance inducing itch, H1-antihistamines are the most frequently used drugs to treat pruritus. However, H1-antihistamines are not fully effective against intractable itch in patients with atopic dermatitis. Given that intractable itch is a clinical problem that markedly decreases quality of life, its treatment in atopic dermatitis is of high importance. Histamine-independent itch may be elicited by various pruritogens, including proteases, cytokines, neuropeptides, lipids, and opioids, and their cognate receptors, such as protease-activated receptors, cytokine receptors, Mas-related G protein-coupled receptors, opioid receptors, and transient receptor potential channels. In addition, cutaneous hyperinnervation is partly involved in itch sensitization in the periphery. It is believed that dry skin is a key feature of intractable itch in atopic dermatitis. Treatment of the underlying conditions that cause itch is necessary to improve the quality of life of patients with atopic dermatitis. This review describes current insights into the pathophysiology of itch and its treatment in atopic dermatitis.

9 April 2025 in Health Science Reports
Verified
Journal Article
Open access
CKChanisa Kiatsurayanon
Chanisa Kiatsurayanon
PDPasinee Deeudomwongsa
Pasinee Deeudomwongsa
PPPitcharat Pituvong
Pitcharat Pituvong
PSPraneet Sajjachareonpong
Praneet Sajjachareonpong
Background and Aims: Lichen planus pigmentosus (LPP) is an uncommon variant of lichen planus which most commonly affects middle‐aged individuals with skin of color. Despite multiple treatment modalities available for LPP, their efficacies are unpredictable and often disappointing. In this study, we aimed to investigate the use of platelet‐rich plasma (PRP) as a novel therapy for LPP.Methods: Twelve patients received three sessions of intradermal PRP injection at a 2‐week interval. Week 0, 2 and 4 were treatment sessions, while Week 6, 8 and 12 were follow‐up visits. Mean melanin index (MI), physician global assessment (PGA) and clinical photographs were assessed at Week 0, 2, 4, 6, 8, and 12, while quartile grading scale (QGS) and patient satisfaction were evaluated at Week 2, 4, 6, 8, and 12. Adverse effects were also recorded.Results: Initial mean MI was 448.19 (18.76) and declined to 409.64 (19.13) at week 12 (p = 0.045). Clinical improvement as evidenced by an increase in mean QGS from Week 2 to Week 12, and a reduction on average PGA score from 3.04 at baseline to 2.21 at Week 6, 2.04 at Week 8, and 2.23 at Week 12, was observed. At Week 12, 5 patients (41.67%) reported more than 50% improvement of LPP lesions.The adverse effects were minimal, consisting primarily of swelling and bruising, which resolved on their own within a few days without the need for treatment.Conclusion: We report the first pilot study utilizing PRP for LPP treatment. The pilot study indicated that PRP significantly improved facial LPP lesions with no significant side effects. Further well‐designed studies with a larger sample size, longer follow‐up duration and possible longer treatment times are necessary to confirm this preliminary observation.Trial Registration: Thai Clinical Trials Registry identification number: TCTR20230202004 (https://www.thaiclinicaltrials.org/show/TCTR20230202004) approved on 02 February 2023.

12 February 2025 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
NSNatsuda Sajjachareonpong
Natsuda Sajjachareonpong
PSPoonnawis Sudtikoonaseth
Poonnawis Sudtikoonaseth
KKKowit Kampirapap
Kowit Kampirapap
MTMonton Tanabodee
Monton Tanabodee
SPSutsarun Prunglumpoo
Sutsarun Prunglumpoo
CKChanisa Kiatsurayanon
Chanisa Kiatsurayanon
Our patient presented with a 5-year history of chronic, asymptomatic papulonodular lesions on the extremities. Over the past 8 months, the lesions have spread to the face and earlobes, and new ulcerative lesions have appeared on both legs. Skin biopsy was compatible with lepromatous leprosy with Lucio phenomenon. Lucio phenomenon is a rare type of leprosy reaction found mostly in neglected lepromatous leprosy cases. Unfortunately, the patient developed pulmonary embolism and passed away. This case report focuses on the clinicopathological characteristics and management of Lucio phenomenon, which is an unusual form of leprosy reaction that often carries a poorer prognosis. Importantly, physicians should be able to differentiate the Lucio phenomenon from other types of leprosy reactions for prompt management.

25 March 2026 in Journal of Current Science and Technology
Verified
Journal Article
Open access
PDF file
PJPolpatt Jitpakdee
Polpatt Jitpakdee
CKChanisa Kiatsurayanon
Chanisa Kiatsurayanon
Lichen planus pigmentosus (LPP) is a chronic acquired hyperpigmentation disorder predominantly affecting sun-exposed areas of the face and neck, for which effective treatment remains challenging. Platelet-rich plasma (PRP) contains growth factors and bioactive mediators, including transforming growth factor-β1 (TGF-β1) and macromolecular activators of phagocytosis, which may modulate melanocyte activity, inflammation, and dermal pigment clearance. This study evaluated whether intradermal autologous PRP provides additive benefit when combined with topical 4% hydroquinone (HQ) in patients with LPP. In this randomized, single-blinded, split-face controlled trial, 15 patients received intradermal PRP injections on one randomly assigned side of the face at baseline, week 2, and week 4, while both sides received nightly topical 4% HQ throughout the 20-week study period. Outcomes included the melanin index measured by Mexameter®, the hemi-modified acquired macular hyperpigmentation and severity index (DPASI), patient satisfaction, and adverse events, assessed through week 20. Both treatment arms showed significant reductions in melanin index from baseline to week 20. Earlier reductions were observed on the PRP-treated side, particularly among patients with mild disease and those naïve to PRP. These findings are consistent with PRP-mediated modulation of melanocyte activity and inflammatory pathways. However, no statistically significant between-side differences were detected at any time point, and effect sizes were small. DPASI scores improved modestly in both groups without significant intergroup differences, while patient satisfaction favored the PRP-treated side. Adverse effects were mild and transient. In conclusion, PRP may exert early localized biological effects on pigmentation through growth factor-mediated mechanisms but did not confer a sustained or clinically dominant advantage over HQ monotherapy. PRP appears to be best positioned as a safe adjunctive therapy in selected patients with LPP.

29 March 2017 in Case Reports in Dermatology
Verified
Journal Article
Open access
PDF file
CKChanisa Kiatsurayanon
Chanisa Kiatsurayanon
JRJinda Rojanamatin
Jinda Rojanamatin
PSPoonawis Sudtikoonaseth
Poonawis Sudtikoonaseth
KKKowit Kampirapap
Kowit Kampirapap
MWMingkwan Wichaidit
Mingkwan Wichaidit
FNFrançois Niyonsaba
François Niyonsaba
Punctate palmoplantar keratoderma (PPPK) is a rare entity with an estimated prevalence rate of 1.17/100,000. PPPK usually presents with bilateral asymptomatic, tiny, hyperkeratotic punctate papules and plaques on the palmoplantar surface. Among the PPPK varieties, the linear presentation is much rarer, and so far there have been only 3 case reports. Here, we report the case of a 27-year-old female Thai patient who presented to our outpatient clinic with unilateral asymptomatic linear thickening lesions on her right sole since childhood. There were no similar lesions on other parts of the body. A histopathologic examination revealed epidermal hyperplasia and hyperkeratosis without columns of parakeratosis or cornoid lamella. The other examinations were normal. The clinical and histological contexts were consistent with a diagnosis of unilateral linear PPPK. The patient was treated with topical 10% urea cream and 10% salicylic acid cream twice daily. To the best of our knowledge, this is the first reported case of unilateral linear PPPK in Thailand, and the fourth reported case worldwide.